BIVI News and Press, BioVie Inc. From 12/08/22

BioVie ( NASDAQ: BIVI ), which has been on a tear since releasing additional data from a Phase 2 trial for its Alzheimer's candidate NE3107 on Tuesday, is closed up 54% Wednesday. The stock is up ~76% since Monday's close. An analysis of blood samples showed a potential i...

Shares of BioVie (NASDAQ: BIVI) were soaring 23.6% higher as of 11:19 a.m. ET on Thursday. The big jump appears to be the result of a delayed positive reaction by investors after the drugmaker reported results earlier this week from a phase 2 study evaluating experimental therapy NE3107. ...

Shares of clinical-stage biotech BioVie (NASDAQ: BIVI) were down 16.5% in midday trading on Tuesday. The company focuses on therapies to treat chronic debilitating conditions and after the market closed on Monday, it released phase 2 trial results for its lead therapy, NE3107, to treat Alzheimer'...

Summary BioVie’s NE3107 has now shown improvement of cognition and function on different Alzheimer’s rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo-controlled trial in Parkinson’s disease with the same dru...

CARSON CITY, Nev., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,...

NE3107-treated patients experienced greater motor control in Parkinson’s trial Patients treated with the combination of NE3107 and levodopa saw improvements in their UPDRS Part 3 (motor) score that is 3+ points superior to patients treated with levodopa alone. This level of sup...

CARSON CITY, Nev., Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver di...

CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver di...

Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...

CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver di...